2026 Annual Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine
The 2026 Annual Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine is jointly sponsored by the American Statistical Association, Amgen, Genentech, Northeastern University, Novo Nordisk, Pfizer, and the University of California at Berkeley. The symposium will take place October 13–14 at the University of California at Berkeley.
While there is much discussion about the potential of AI and modern machine learning tools to transform the drug development paradigm, there is a growing recognition of the paucity of research about the opportunities, inevitable pitfalls, and unintended consequences of the digital revolution in this important area of application. As we move toward personalized and truly evidence-based medicine, the use of AI and machine learning to optimize drug deployment raises a whole different set of challenges.
This forum is, therefore, expected to serve as a platform for distinguished statisticians, data scientists, regulators, and other professionals to address the challenges and opportunities of AI in pharmaceutical medicine; to foster collaboration among industry, academia, regulatory agencies, and professional associations; and to propose recommendations with policy implications for proper implementation of AI in promoting public health.